• Quest Diagnostics (NYSE:DGX) has partnered with Guardant Health to offer the FDA approved Shield blood test for colorectal cancer screening.
• The agreement will make Shield available nationwide through Quest’s testing ecosystem, expanding access for patients and clinicians.
• The collaboration focuses on a blood based option for colorectal cancer screening that may support broader adoption of preventive care.

For you as an investor, this move plugs directly into what Quest Diagnostics already does at scale, processing tests across primary care, specialist offices and health systems. Colorectal cancer screening is a large, established category in diagnostics, and a blood based test sits alongside existing stool based tests and colonoscopy. The partnership adds a new product type to Quest’s menu in an area where adherence and convenience are central issues for patients and physicians.

Looking ahead, key variables to watch include how clinicians incorporate Shield into their screening workflows and how payers treat reimbursement over time. Adoption within Quest’s national network may become an important reference point when evaluating NYSE:DGX’s role in preventive testing and its broader push into oncology related diagnostics.

Stay updated on the most important news stories for Quest Diagnostics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Quest Diagnostics.

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$200.90 versus a consensus target of US$218.50, the price sits about 8% below analyst expectations.
• ✅ Simply Wall St Valuation: Simply Wall St estimates Quest Diagnostics is trading around 33.8% below its fair value, which screens as undervalued.
• ✅ Recent Momentum: The 30 day return of roughly 5.3% suggests the shares have been moving up recently.

There is only one way to know the right time to buy, sell or hold Quest Diagnostics. Head to the Simply Wall St company report for the latest analysis of Quest Diagnostics's Fair Value.

Key Considerations

• 📊 The Guardant Health partnership plugs a new blood based colorectal test into Quest’s US$11.0b revenue platform, reinforcing its role in preventive testing.
• 📊 It may be useful to monitor clinician uptake, reimbursement decisions and any impact on Quest’s earnings per share, currently US$8.99 with a P/E of 22.3x versus the Healthcare industry average of about 22.3x.
• ⚠️ Simply Wall St flags a high level of debt as a minor risk, which is worth keeping in mind as Quest invests around oncology related diagnostics.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Quest Diagnostics analysis. Alternatively, you can check out the community page for Quest Diagnostics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.